Detalhe da pesquisa
1.
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
Int J Cancer
; 145(3): 649-661, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30653256
2.
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.
Int J Cancer
; 142(12): 2589-2598, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29363116
3.
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
Cancer
; 124(24): 4667-4675, 2018 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30383906
4.
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Lancet Oncol
; 16(3): 328-37, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25701171
5.
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Oncologist
; 19(10): 1100-9, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25232040
6.
Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancer.
Respiration
; 87(3): 204-10, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24192055
7.
Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung).
J Immunother
; 45(2): 89-99, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34908007
8.
Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer.
Front Oncol
; 11: 670483, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33959513
9.
De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer.
Front Oncol
; 11: 640048, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33898315
10.
A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung).
Front Pharmacol
; 12: 599598, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33796020
11.
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.
Ther Adv Med Oncol
; 13: 1758835921996509, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34408792
12.
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
Lung Cancer
; 154: 131-141, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33667718
13.
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
Lung Cancer
; 148: 159-165, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32927350
14.
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).
Front Oncol
; 10: 569715, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33643895
15.
Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients.
Int J Cancer
; 124(7): 1669-74, 2009 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19107936
16.
Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Oncol Res Treat
; 42(5): 243-255, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30995666
17.
[Management of adverse events in immune oncology - Practical aspects of immune-related adverse events during immune oncological treatment]. / Nebenwirkungsmanagement in der Immunonkologie.
Dtsch Med Wochenschr
; 144(5): 346-353, 2019 03.
Artigo
em Alemão
| MEDLINE | ID: mdl-30699440
18.
Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab.
Oncol Lett
; 17(6): 4891-4900, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31186697
19.
ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.
Med Oncol
; 35(7): 106, 2018 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29905882
20.
Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine.
Lung Cancer
; 56(1): 115-23, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17196704